Open AccessP584: OVERALL SURVIVAL WITH INTENSIVE CHEMOTHERAPY (IC) VS NON‐IC IN PATIENTS (PTS) WITH NEWLY DIAGNOSED (ND) AML FROM THE CONNECT® MYELOID DISEASE REGISTRY INELIGIBLE FOR RANDOMIZED CLINICAL TRIALS (RCT)
Author(s) -
Erba H.,
Pollyea D.,
Sekeres M.,
GarciaManero G.,
Seiter K.,
DeGutis I.,
Kiselev P.,
McBride A.,
Yu E.,
Roboz G.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845224.64123.95
Subject(s) - medicine , hazard ratio , regimen , randomized controlled trial , population , cohort , comorbidity , confidence interval , environmental health